Top

Published in:

2019 | OriginalPaper | Chapter

Real-World Evidence and Hepatitis C

Authors : Michael W. Fried, David R. Nelson

Published in: HCV: The Journey from Discovery to a Cure

Publisher: Springer International Publishing

Activate our intelligent search to find suitable subject content or patents.

search-config

AI-assisted search

Off

Abstract

Direct-acting antiviral agents (DAAs) are the treatment of choice for patients with chronic hepatitis C. Their efficacy across diverse patient populations and safety among those with all stages of liver disease, including cirrhosis, have been repeatedly demonstrated in studies encompassing all classes of DAAs. Real-world evidence has confirmed that DAA therapies used in usual clinical practice achieved similar rates of sustained virological response when compared to those reported in rigorously controlled clinical trials. These data, developed from large cohort studies performed around the world, have instilled greater confidence in the management of patients with chronic hepatitis C using DAAs. Furthermore, real-world evidence contributed to better understanding the strengths and limitations of DAA treatment among unique populations of patients with chronic hepatitis C who were underrepresented in the original registration trials of these agents.

Dont have a licence yet? Then find out more about our products and how to get one now:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

über 102.000 Bücher
über 537 Zeitschriften

aus folgenden Fachgebieten:

Automobil + Motoren
Bauwesen + Immobilien
Business IT + Informatik
Elektrotechnik + Elektronik
Energie + Nachhaltigkeit
Finance + Banking
Management + Führung
Marketing + Vertrieb
Maschinenbau + Werkstoffe
Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

inform now

Springer Professional "Technik"

Online-Abonnement

Mit Springer Professional "Technik" erhalten Sie Zugriff auf:

über 67.000 Bücher
über 390 Zeitschriften

aus folgenden Fachgebieten:

Automobil + Motoren
Bauwesen + Immobilien
Business IT + Informatik
Elektrotechnik + Elektronik
Energie + Nachhaltigkeit
Maschinenbau + Werkstoffe

Jetzt Wissensvorsprung sichern!

inform now

previous chapter Development of ZEPATIER®

next chapter The Benefit of Direct-Acting Antiviral HCV Cure Therapies

Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, Romero-Gomez M et al (2014) Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 370:1889–1898PubMedCrossRef

Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, Nahass R et al (2014) Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 370:1483–1493PubMedCrossRef

Forns X, Lee SS, Valdes J, Lens S, Ghalib R, Aguilar H, Felizarta F et al (2017) Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect Dis 17:1062–1068PubMedCrossRef

Zeuzem S, Foster GR, Wang S, Asatryan A, Gane E, Feld JJ, Asselah T et al (2018) Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection. N Engl J Med 378:354–369PubMedCrossRef

Hezode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, Bronowicki JP et al (2009) Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 360:1839–1850PubMedCrossRef

Poordad F, McCone Jr J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM et al (2011) Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 364:1195–1206PubMedPubMedCentralCrossRef

Sherman RE, Anderson SA, Dal Pan GJ, Gray GW, Gross T, Hunter NL, LaVange L et al (2016) Real-world evidence – what is it and what can it tell us? N Engl J Med 375:2293–2297CrossRefPubMed

Califf RM, Robb MA, Bindman AB, Briggs JP, Collins FS, Conway PH, Coster TS et al (2016) Transforming evidence generation to support health and health care decisions. N Engl J Med 375:2395–2400PubMedCrossRef

Sherman RE, Davies KM, Robb MA, Hunter NL, Califf RM (2017) Accelerating development of scientific evidence for medical products within the existing US regulatory framework. Nat Rev Drug Discov 16:297–298PubMedCrossRef

10.

Administration USFaD (2018) 21st Century Cures Act. US FDAxt

11.

Galson SK, Simon G (2016) Real-world evidence to guide the approval and use of new treatments. National Academy of Medicine, WashingtonCrossRef

12.

Mishra P, Florian J, Peter J, Vainorius M, Fried MW, Nelson DR, Birnkrant D (2017) Public-private partnership: targeting real-world data for hepatitis C direct-acting antivirals. Gastroenterology 153:626–631PubMedCrossRef

13.

AASLD-IDSA (2018) HCV guidance: recommendations for testing, management, and treating hepatitis C

14.

European Association for the Study of the Liver (2018) European Association for the Study of the L. EASL recommendations on treatment of hepatitis C 2018. J Hepatol 69:461–511CrossRef

15.

Hezode C, Fontaine H, Dorival C, Larrey D, Zoulim F, Canva V, de Ledinghen V et al (2013) Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) – NCT01514890. J Hepatol 59:434–441PubMedCrossRef

16.

Backus LI, Belperio PS, Shahoumian TA, Loomis TP, Mole LA (2015) Effectiveness of sofosbuvir-based regimens in genotype 1 and 2 hepatitis C virus infection in 4026 U.S. Veterans. Aliment Pharmacol Ther 42:559–573PubMedCrossRef

17.

Ingiliz P, Christensen S, Kimhofer T, Hueppe D, Lutz T, Schewe K, Busch H et al (2016) Sofosbuvir and ledipasvir for 8 weeks for the treatment of chronic hepatitis C virus (HCV) infection in HCV-monoinfected and HIV-HCV-coinfected individuals: results from the german hepatitis C cohort (GECCO-01). Clin Infect Dis 63:1320–1324PubMedCrossRef

18.

Tapper EB, Bacon BR, Curry MP, Dieterich DT, Flamm SL, Guest LE, Kowdley KV et al (2017) Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: the Trio Health study. J Viral Hepat 24:22–27PubMedCrossRef

19.

McLauchlan J, Innes H, Dillon JF, Foster G, Holtham E, McDonald S, Wilkes B et al (2017) Cohort profile: the hepatitis C virus (HCV) Research UK Clinical Database and Biobank. Int J Epidemiol 46:1391–1391hPubMedPubMedCentralCrossRef

20.

Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P et al (2011) Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 364:2405–2416PubMedCrossRef

21.

Hezode C, Fontaine H, Dorival C, Zoulim F, Larrey D, Canva V, De Ledinghen V et al (2014) Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology 147:132–142. e134PubMedCrossRef

22.

Gordon SC, Muir AJ, Lim JK, Pearlman B, Argo CK, Ramani A, Maliakkal B et al (2015) Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET. J Hepatol 62:286–293PubMedCrossRef

23.

Forns X, Lawitz E, Zeuzem S, Gane E, Bronowicki JP, Andreone P, Horban A et al (2014) Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology 146:1669–1679. e1663PubMedCrossRef

24.

Lawitz E, Lalezari JP, Hassanein T, Kowdley KV, Poordad FF, Sheikh AM, Afdhal NH et al (2013) Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis 13:401–408PubMedCrossRef

25.

Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A, DeJesus E et al (2014) Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 384:1756–1765PubMedCrossRef

26.

Sulkowski MS, Vargas HE, Di Bisceglie AM, Kuo A, Reddy KR, Lim JK, Morelli G et al (2016) Effectiveness of simeprevir plus sofosbuvir, with or without ribavirin, in real-world patients with HCV genotype 1 infection. Gastroenterology 150:419–429PubMedCrossRef

27.

Yee BE, Nguyen NH, Jin M, Lutchman G, Lim JK, Nguyen MH (2016) Lower response to simeprevir and sofosbuvir in HCV genotype 1 in routine practice compared with clinical trials. BMJ Open Gastroenterol 3:e000056PubMedPubMedCentralCrossRef

28.

Lawitz E, Matusow G, DeJesus E, Yoshida EM, Felizarta F, Ghalib R, Godofsky E et al (2016) Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: a phase 3 study (OPTIMIST-2). Hepatology 64:360–369PubMedCrossRef

29.

Kwo P, Gitlin N, Nahass R, Bernstein D, Etzkorn K, Rojter S, Schiff E et al (2016) Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study. Hepatology 64:370–380PubMedCrossRef

30.

Afdhal NH, Serfaty L (2016) Effect of registries and cohort studies on HCV treatment. Gastroenterology 151:387–390PubMedCrossRef

31.

Terrault N et al (2015). Hepatology 62:256ACrossRef

32.

Curry MP et al (2015). Hepatology 62:755A

33.

Afdhal NH (2016). Gastroenterology 150:S1097CrossRef

34.

Poi S et al (2015). J Hepatol 62:S258CrossRef

35.

Zuckerman E et al (2016). J Hepatol 64:S137CrossRef

36.

Hinrichsen H et al (2016). Hepatology 64:S159CrossRef

37.

Wetzel TM et al (2015). Hepatology 62:737A

38.

Hezode C et al (2015). Hepatology 62:314A

39.

Terrault NA, Zeuzem S, Di Bisceglie AM, Lim JK, Pockros PJ, Frazier LM, Kuo A et al (2016) Effectiveness of ledipasvir-sofosbuvir combination in patients with hepatitis C virus infection and factors associated of sustained virologic response. Gastroenterology 151:1131–1140.e5PubMedCrossRef

40.

Ioannou GN, Beste LA, Chang MF, Green PK, Lowy E, Tsui JI, Su F et al (2016) Effectiveness of sofosbuvir, ledipasvir/sofosbuvir, or paritaprevir/ritonavir/ombitasvir and dasabuvir regimens for treatment of patients with hepatitis C in the veterans affairs national health care system. Gastroenterology 151:457–471 e455PubMedCrossRef

41.

Berg T, Naumann U, Stoehr A, Sick C, Teuber G, Schiffeiholz W, Mauss S, Hettinger J, Kleine H, Pangerl A, Niederau C (2018) First real world data on safety and effectiveness of glecaprevir/pibrentasvir treatment of patients with chronic hepatitis C: data from the German Hepatitis C Registry. J Hepatol 68:S37. Abstract GS-007CrossRef

42.

Carrat F (2017) Clinical outcomes after SVR: ANRS CO22 HEPATHER. Hepatology 2017:Abstract (LB-28)

43.

Ioannou GN, Green PK, Beste LA, Mun EJ, Kerr KF, Berry K (2018) Development of models estimating the risk of hepatocellular carcinoma after antiviral treatment for hepatitis C. J Hepatol 69:1088–1098PubMedPubMedCentralCrossRef

44.

Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, Shiffman ML et al (2014) Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 370:1879–1888PubMedCrossRef

45.

Su F, Green PK, Berry K, Ioannou GN (2017) The association between race/ethnicity and the effectiveness of direct antiviral agents for hepatitis C virus infection. Hepatology 65:426–438PubMedCrossRef

46.

German P, Mathias A, Brainard D, Kearney BP (2016) Clinical pharmacokinetics and pharmacodynamics of ledipasvir/sofosbuvir, a fixed-dose combination tablet for the treatment of hepatitis C. Clin Pharmacokinet 55:1337–1351PubMedCrossRef

47.

Tapper EB, Bacon BR, Curry MP, Dieterich DT, Flamm SL, Guest LE, Kowdley KV et al (2016) Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real-world cohort study. Hepatology 64:1893–1899PubMedCrossRef

48.

Poordad F, Felizarta F, Asatryan A, Sulkowski MS, Reindollar RW, Landis CS, Gordon SC et al (2017) Glecaprevir and pibrentasvir for 12 weeks for HCV genotype 1 infection and prior direct-acting antiviral treatment. Hepatology 66:389–397PubMedCrossRef

49.

Gane E, Lawitz E, Pugatch D, Papatheodoridis G, Brau N, Brown A, Pol S et al (2017) Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment. N Engl J Med 377:1448–1455PubMedCrossRef

50.

Roth D, Nelson DR, Bruchfeld A, Liapakis A, Silva M, Monsour Jr H, Martin P et al (2015) Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet 386:1537–1545PubMedCrossRef

51.

Saxena V, Koraishy FM, Sise ME, Lim JK, Schmidt M, Chung RT, Liapakis A et al (2016) Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function. Liver Int 36:807–816PubMedPubMedCentralCrossRef

52.

Butt AA, Ren Y, Puenpatom A, Arduino JM, Kumar R, Abou-Samra AB (2018) HCV treatment initiation in persons with chronic kidney disease in the directly acting antiviral agents era: results from ERCHIVES. Liver Int 38:1411–1417PubMedCrossRef

53.

Colombo M, Aghemo A, Liu H, Zhang J, Dvory-Sobol H, Hyland R, Yun C et al (2017) Treatment with ledipasvir-sofosbuvir for 12 or 24 weeks in kidney transplant recipients with chronic hepatitis C virus genotype 1 or 4 infection: a randomized trial. Ann Intern Med 166:109–117PubMedCrossRef

54.

Terrault NA, McCaughan GW, Curry MP, Gane E, Fagiuoli S, Fung JYY, Agarwal K et al (2017) International Liver Transplantation Society consensus statement on hepatitis C management in liver transplant candidates. Transplantation 101:945–955PubMedCrossRef

55.

Terrault NA, Berenguer M, Strasser SI, Gadano A, Lilly L, Samuel D, Kwo PY et al (2017) International Liver Transplantation Society consensus statement on hepatitis C management in liver transplant recipients. Transplantation 101:956–967PubMedCrossRef

56.

Saxena V, Khungar V, Verna EC, Levitsky J, Brown Jr RS, Hassan MA, Sulkowski MS et al (2017) Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: results from the HCV-TARGET study. Hepatology 66:1090–1101PubMedCrossRef

57.

Manns M, Samuel D, Gane EJ, Mutimer D, McCaughan G, Buti M, Prieto M et al (2016) Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis 16:685–697PubMedCrossRef

58.

Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, Brown Jr RS, Fried MW et al (2015) Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 149:649–659PubMedCrossRef

59.

Curry MP, O’Leary JG, Bzowej N, Muir AJ, Korenblat KM, Fenkel JM, Reddy KR et al (2015) Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med 373:2618–2628PubMedCrossRef

60.

El-Sherif O, Jiang ZG, Tapper EB, Huang KC, Zhong A, Osinusi A, Charlton M et al (2018) Baseline factors associated with improvements in decompensated cirrhosis after direct-acting antiviral therapy for hepatitis C virus infection. Gastroenterology 154:2111–2121 e2118PubMedCrossRef

61.

Foster GR, Irving WL, Cheung MC, Walker AJ, Hudson BE, Verma S, McLauchlan J et al (2016) Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 64:1224–1231PubMedCrossRef

62.

Naggie S, Cooper C, Saag M, Workowski K, Ruane P, Towner WJ, Marks K et al (2015) Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 373:705–713PubMedPubMedCentralCrossRef

63.

Rockstroh JK, Lacombe K, Viani RM, Orkin C, Wyles D, Luetkemeyer AF, Soto-Malave R et al (2018) Efficacy and safety of glecaprevir/pibrentasvir in patients coinfected with hepatitis C virus and human immunodeficiency virus type 1: the EXPEDITION-2 Study. Clin Infect Dis 67:1010–1017PubMedPubMedCentralCrossRef

64.

Bhattacharya D, Belperio PS, Shahoumian TA, Loomis TP, Goetz MB, Mole LA, Backus LI (2017) Effectiveness of all-oral antiviral regimens in 996 human immunodeficiency virus/hepatitis C virus genotype 1-coinfected patients treated in routine practice. Clin Infect Dis 64:1711–1720PubMedCrossRef

65.

Sogni P, Gilbert C, Lacombe K, Piroth L, Rosenthal E, Miailhes P, Gervais A et al (2016) All-oral direct-acting antiviral regimens in HIV/hepatitis C virus-coinfected patients with cirrhosis are efficient and safe: real-life results from the prospective ANRS CO13-HEPAVIH Cohort. Clin Infect Dis 63:763–770PubMedCrossRef

Title: Real-World Evidence and Hepatitis C
Authors: Michael W. Fried
David R. Nelson
Publisher: Springer International Publishing
Book: HCV: The Journey from Discovery to a Cure
Print ISBN: 978-3-030-28399-5

Electronic ISBN: 978-3-030-28400-8

Copyright Year: 2019
DOI: https://doi.org/10.1007/7355_2019_63